Indaptus Therapeutics Inc
NASDAQ:INDP

  • LAST PRICE
    1.0300
  • TODAY'S CHANGE (%)
    0.0300 (3.0000%)
  • Bid / Lots
    1.0200/ 2
  • Ask / Lots
    1.1200/ 1
  • Open / Previous Close
    0.9594 / 1.0000
  • Day Range
    0.9594
    1.0700
  • 52 Week Range
    0.8400
    3.1000
  • Volume
    42,590

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 22, 2024

      Show headlines and story abstract

    • 8:36AM ET on Friday Nov 22, 2024 by Dow Jones
      Companies Mentioned: INDP

      Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement

      NEW YORK, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus"), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that it has entered into securities purchase agreements with investors, including an officer of Indaptus, for the issuance and sale of an aggregate of 1,817,017 of its shares of common stock. In a concurrent private placement, Indaptus has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 1,817,017 of its shares of common stock. The combined effective purchase price for each share of common stock and associated warrants is $1.175. The warrants will have an exercise price of $1.05 per share, will be immediately exercisable upon issuance and have a term of five years from the date of issuance. The closing of the offering is expected to take place on or about November 25, 2024, subject to the satisfaction of customary closing conditions.

    • 8:36AM ET on Friday Nov 22, 2024 by Dow Jones
      Companies Mentioned: INDP

      Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement

      NEW YORK, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus"), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that it has entered into securities purchase agreements with investors, including an officer of Indaptus, for the issuance and sale of an aggregate of 1,817,017 of its shares of common stock. In a concurrent private placement, Indaptus has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 1,817,017 of its shares of common stock. The combined effective purchase price for each share of common stock and associated warrants is $1.175. The warrants will have an exercise price of $1.05 per share, will be immediately exercisable upon issuance and have a term of five years from the date of issuance. The closing of the offering is expected to take place on or about November 25, 2024, subject to the satisfaction of customary closing conditions.

  • Nov 13, 2024

  • Nov 12, 2024

      Show headlines and story abstract

    • 8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
      Companies Mentioned: INDP
      Other comprehensive income (loss): Reclassification adjustment for interest earned on marketable securities included in net loss - (140,567) - (430,993) Change in unrealized gain on marketable securities - 6,412 - 334,559 ---------- ---------- ----------- ----------- Comprehensive loss $(3,069,036) $(4,056,543) $(10,890,980) $(11,517,125) ========== ========== =========== =========== Unaudited Condensed Consolidated Statements of Cash Flows For the Nine Months Ended September 30, --------------------------- 2024 2023 ------------ ------------ Cash flows from operating activities: Net loss $(10,890,980) $(11,420,691) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation 735 964 Stock-based compensation 2,001,727 2,220,413 Interest earned on marketable securities - (430,993) Changes in operating assets and liabilities: Prepaid expenses and other current and non- current assets 634,419 (84,568) Accounts payable and other current liabilities (673,829) (1,088,785) Operating lease right-of-use asset and liability, net 487 290 ----------- ----------- Net cash used in operating activities (8,927,441) (10,803,370) ----------- ----------- Cash flows from investing activities: Maturity of marketable securities - 24,000,000 Purchase of marketable securities - (6,859,432) ----------- ----------- Net cash provided by investing activities - 17,140,568 ----------- ----------- Cash flows from financing activities: Proceeds from issuance of shares of common stock and warrants 3,375,590 - Issuance costs (429,516) - ----------- ----------- Net cash provided by financing activities 2,946,074 - ----------- ----------- Net (decrease) increase in cash and cash equivalents (5,981,367) 6,337,198 Cash and cash equivalents at beginning of period 13,362,053 9,626,800 ----------- ----------- Cash and cash equivalents at end of period $ 7,380,686 $ 15,963,998 =========== =========== Noncash investing and financing activities Transaction costs in accounts payable and other current liabilities $ 129,993 $ - Change in unrealized gain/loss on marketable securities $ - $ (96,434) ASC 842 lease renewal option exercise $ - $ 236,506 Reclassification of security deposit $ - $ 16,477

    • 8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
      Companies Mentioned: INDP

Peers Headlines